{
  "id": 4668061,
  "title": "Immediate evolocumab after a heart attack improves LDL-cholesterol goals but not early cardiovascular outcomes",
  "url": "https://urgent.news/2026/08/31/immediate-evolocumab-after-a-heart-attack-improves-ldl-cholesterol",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-31T15:40:08.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-evolocumab-heart-ldl-cholesterol-goals.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not observed compared with standard care. These were the main findings of the AMUNDSEN trial presented in a Hot Line session at ESC Congress 2026 and published…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}